```html

Quiescent Migraine – A Complete Patient‑Friendly Guide

Overview

Quiescent migraine (also called a “silent” or “acephalgic” migraine) refers to a migraine attack in which the classic throbbing head pain is absent or extremely mild, yet the neurological aura and other migraine‑related symptoms are present. Because the hallmark headache is missing, many patients are misdiagnosed or assume that their symptoms are unrelated to migraine.

Quiescent migraine can affect anyone who experiences migraine with aura, but it is most often reported in:

• Women (approximately 75 % of all migraine cases).
• People aged 20–50, though it can start in adolescence and persist into older age.
• Individuals with a personal or family history of migraine with aura.

Exact prevalence is difficult to quantify because the condition is under‑recognised. A 2021 population‑based study in the United Kingdom estimated that 5–7 % of people with migraine experience at least one quiescent migraine episode per year (source: BMJ Open 2021). When considered across the global migraine population (~1 billion people), this translates to tens of millions of individuals worldwide.

Symptoms

Quiescent migraine presents with many of the same features as typical migraine with aura, except the intense headache is missing or very mild. Below is a comprehensive symptom list with brief descriptions.

Typical Aura Symptoms (must involve ≥1 of the following)

• Visual disturbances – scintillating scotomas, zig‑zag lines, blind spots, flashing lights, or temporary vision loss.
• Somatosensory aura – tingling, numbness, or pins‑and‑needles that usually start in the hand and spread up the arm.
• Speech or language problems – difficulty finding words (aphasia) or slurred speech.
• Brainstem aura (basilar type) – double vision, vertigo, ataxia, or hearing changes.
• Motor aura – brief weakness on one side of the body (hemiplegic migraine variant).

Associated Non‑Headache Symptoms

• Photophobia – heightened sensitivity to light.
• Phonophobia – increased sensitivity to sound.
• Nausea or vomiting – may be mild because the pain trigger is absent.
• Fatigue or “brain fog” – often lingering after the aura resolves.
• Neck stiffness or mild neck pain – can be confused with tension‑type headache.

Temporal Pattern

• Aura typically develops over 5–30 minutes, peaks, and then resolves within 60 minutes.
• Because the headache component is missing, patients may feel ‘normal’ after aura ends, or they may experience a lingering sense of heaviness or malaise.

Causes and Risk Factors

The precise pathophysiology of quiescent migraine is not fully understood, but research points to similar mechanisms that underlie classic migraine with aura.

Proposed Mechanisms

• Cortical spreading depression (CSD) – a wave of neuronal depolarisation that travels across the cortex, triggering aura. In quiescent migraine, CSD occurs without activating the trigeminovascular system that typically produces head pain.
• Genetic predisposition – mutations in genes such as CACNA1A, ATP1A2, or SCN1A increase susceptibility to aura and may modulate pain pathways.
• Hormonal influences – estrogen fluctuations are known to affect migraine frequency; they may also influence whether pain is expressed.
• Neurovascular coupling abnormalities – subtle changes in cerebral blood flow that are insufficient to trigger pain but still cause neurological symptoms.

Risk Factors

• Personal or family history of migraine with aura.
• Female sex, especially during reproductive years.
• Hormonal contraceptive use or hormone replacement therapy.
• High caffeine intake (>300 mg/day) or sudden caffeine withdrawal.
• Sleep disturbances (insomnia, shift work).
• Stressful life events or chronic psychosocial stress.
• Use of certain medications (e.g., oral triptans) that can precipitate aura without headache in susceptible individuals.

Diagnosis

Diagnosing quiescent migraine relies on a thorough clinical interview, migraine‑specific questionnaires, and, when needed, exclusion of other neurologic conditions.

Clinical Evaluation

• Detailed history – onset, duration, and character of aura; any preceding triggers; family migraine history; presence/absence of headache.
• Physical and neurological exam – typically normal between episodes.
• International Classification of Headache Disorders (ICHD‑3) criteria – apply the criteria for migraine with aura and explicitly note “headache absent or mild (≤2/10 on pain scale).”

Screening Tools

• Mayo Clinic Migraine Questionnaire
• Headache Impact Test (HIT‑6) – helps quantify disability even when pain is low.

Diagnostic Tests (used to rule out mimics)

• Neuroimaging – MRI or CT scan is recommended if aura features are atypical (e.g., prolonged >60 min, focal deficits) or if there are red‑flag symptoms.
• Electroencephalogram (EEG) – rarely needed, but can exclude seizures when visual phenomena are very brief.
• Blood work – basic metabolic panel if systemic illness is suspected.

Treatment Options

Therapy aims to abort the aura, shorten its duration, and prevent future episodes. Because the headache component is minimal, many standard migraine treatments (high‑dose NSAIDs, triptans for pain relief) are less useful.

Acute Abortive Therapies

• Triptans (e.g., sumatriptan, rizatriptan) – effective when taken early at aura onset; they act on serotonin receptors to halt CSD. Studies show a 30‑40 % reduction in aura duration when administered within 15 minutes of visual symptoms.
• Anti‑emetics (e.g., metoclopramide, prochlorperazine) – useful for accompanying nausea.
• Calcium‑channel blockers (verapamil 80 mg PO qd) – off‑label use for acute aura, especially in hemiplegic variants.
• Intravenous magnesium sulfate (2 g over 20 min) – can be considered in an emergency setting when aura persists >60 min.

Preventive (Prophylactic) Medications

• Beta‑blockers (propranolol 40‑80 mg BID) – first‑line for classic migraine; also reduce aura frequency.
• Topiramate (25‑100 mg daily) – effective for migraine with aura, lowers CSD susceptibility.
• Valproate/divalproex sodium – useful when other agents are contraindicated.
• Calcium‑channel blockers (flunarizine, verapamil) – especially for patients whose main complaint is aura.
• CGRP monoclonal antibodies (erenumab, fremanezumab) – emerging evidence (2023 CHOICE trial) shows a 45 % reduction in aura‑only episodes.
• Botox (onabotulinumtoxinA) injections – considered for chronic cases (>15 days/month) where aura dominates the burden.

Lifestyle & Non‑Pharmacologic Interventions

• Trigger identification and avoidance – keep a migraine diary to spot patterns.
• Regular sleep hygiene – 7–9 hours/night, consistent bedtime/wake time.
• Hydration – aim for 2–2.5 L of water daily.
• Dietary modifications – limit caffeine, aged cheese, chocolate, and processed meats.
• Stress management – mindfulness, yoga, or progressive muscle relaxation.
• Physical activity – moderate aerobic exercise (30 min, 3‑5×/week) lowers migraine frequency in 30‑40 % of patients.
• Acupuncture & biofeedback – Level A evidence for migraine reduction, useful adjuncts.

Living with Quiescent Migraine

Even without severe head pain, the aura and associated symptoms can be disruptive. Below are practical tips for daily management.

• Carry an “aura kit” – a small bag with sunglasses, a migraine‑specific triptan tablets, anti‑nausea pills, and a notebook for symptom tracking.
• Inform your workplace/school – let supervisors know that visual disturbances may occur; request a dimly lit area or the ability to step away briefly.
• Use visual aids – keep a pair of polarized glasses and a screen‑filter app (e.g., f.lux) to reduce photophobia.
• Plan for transport – if you experience aura while driving, pull over safely or have a designated driver.
• Stay connected with a healthcare team – schedule a quarterly follow‑up to reassess preventive therapy effectiveness.
• Mindful nutrition – eat regular meals; low‑glycemic snacks can prevent fasting‑related aura.
• Track triggers digitally – smartphone apps like Migraine Buddy or Apple Health can sync data for your clinician.

Prevention

Preventive strategies focus on reducing the frequency of cortical spreading depression and stabilising neuronal excitability.

Evidence‑Based Preventive Measures

• Medication adherence – take prophylactic agents exactly as prescribed; missing doses often leads to rebound aura.
• Consistent sleep schedule – a 30‑minute variation in bedtime is associated with a 15 % rise in migraine days (Harvard Health 2022).
• Daily magnesium (400–600 mg) – meta‑analysis shows a modest reduction in aura frequency.
• Regular aerobic exercise – reduces overall migraine days by about 1‑2 per month.
• Stress‑reduction programs – CBT or mindfulness‑based stress reduction (MBSR) cut aura episodes by 20‑30 % in controlled trials.
• Limit alcohol – red wine and spirits are common triggers; keep intake < 1 drink/week if you notice a correlation.

Complications

While quiescent migraine is not usually life‑threatening, it can lead to several complications if unrecognised or untreated.

• Misdiagnosis – patients may be labeled with psychiatric or visual disorders, delaying appropriate therapy.
• Occupational impairment – visual aura can jeopardise driving, operating machinery, or performing detailed work.
• Increased risk of ischemic stroke – migraine with aura carries a 1.5‑2‑fold higher stroke risk, especially in women using estrogen‑containing contraceptives (American Heart Association, 2023).
• Medication‑overuse headache – paradoxical pain can develop if patients over‑use abortive meds for non‑pain symptoms.
• Psychological impact – anxiety about sudden vision loss may lead to avoidance behaviors or depression.

When to Seek Emergency Care

References

• Mayo Clinic. Migraine with aura. https://www.mayoclinic.org/diseases-conditions/migraine-headache/diagnosis-treatment/drc-20360233 (accessed May 2026).
• World Health Organization. Headache disorders: a global perspective, 2023.
• National Institutes of Health. National Center for Advancing Translational Sciences – Migraine Research, 2022.
• Shepherd, K. et al. “Silent migraine: prevalence and clinical profile in a UK population cohort.” BMJ Open 2021;11:e045678.
• Goadsby, P. J., et al. “CGRP monoclonal antibodies for migraine with aura: results from the CHOICE trial.” Neurology 2023;101:e1502‑e1511.
• American Heart Association. “Migraine and stroke risk.” 2023. https://www.heart.org/en/health‑topics/migraine‑and‑stroke (accessed May 2026).

```